News & Updates
Filter by Specialty:
BRCA-negative ovarian cancer gets PFS gains with pembrolizumab plus olaparib
First-line treatment with chemotherapy plus pembrolizumab followed by maintenance with pembrolizumab plus olaparib, with or without bevacizumab, appears to prolong progression-free survival (PFS) in advanced epithelial ovarian cancer without BRCA 1/2 mutations, according to data from the phase III ENGOT-ov43/GOG-3036/KEYLYNK-001 trial.
BRCA-negative ovarian cancer gets PFS gains with pembrolizumab plus olaparib
08 May 2025
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
In the interim analysis of the phase III BRIGHT-2 study, adding the CDK4/6 inhibitor bireociclib to fulvestrant prolongs progression-free survival (PFS) in Chinese women with HR+/HER2- advanced breast cancer (ABC) who progressed on or after endocrine therapy (ET).
Add-on bireociclib promising for HR+/HER2- ABC following ET failure
07 May 2025
Cancer therapy takes a toll on women’s sexual health
In women being treated for cervical cancer, chemotherapy and radiotherapy appear to have a substantial and lasting negative effect on sexual health, including satisfaction and desire, as shown in a descriptive cross-sectional study conducted in Brazil.